Rheumatology

September 28, 2020

Autologous hematopoietic stem cell transplants (AHSCT) improve the quality of life in patients with systemic sclerosis (SSc), researchers say.

September 28, 2020

Various drug therapies, including several cytokine blockers, are showing promise in addressing COVID-19 related cytokine storm syndrome, says Dr. Randall Cron of Children’s Hospital of Alabama.

September 26, 2020

Today, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

September 25, 2020

In a review recently published in Current Osteoporosis Reports, Sarah French, M.D., a rheumatologist with the University of California at San Francisco, summarizes performance quality measures for osteoporosis using Centers for Medicare and Medicaid measures for pay-for-performance programs. In this interview, Dr. French shares with us her findings.

September 25, 2020

The use of biologics, JAK inhibitors and small molecule medications has become increasingly common for patients with psoriatic arthritis. Findings from the recent Psoriatic Arthritis In America 2020 survey by Health Union shows that of 1,120 patients surveyed, most patients (61 percent) are satisfied with the care they receive from their doctors, but they still struggle with flares and only 12 percent are satisfied with their care plan. In this interview, Brian Green, vice president of community development at Health Union, reviews the results of their latest survey.

September 24, 2020

Type I Interferon Inhibition Could Benefit Systemic Lupus Erythematosus

September 24, 2020

The approval of tocilizumab for giant cell arteritis as a glucocorticoid-sparing treatment is the most significant development in the management of this condition over the past four years, a review of the literature suggests.

September 23, 2020

Some drugs used to treat lupus and other connective tissue diseases have been shown to increase cardiovascular risks. Even so, those drugs remain effective in addressing disease symptoms, and a leading rheumatology researcher has suggested that concerns may not be fully warranted.

September 23, 2020

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​

September 22, 2020

Black patients with knee osteoarthritis have worse outcomes than their white counterparts, shows a new study.

September 22, 2020

Cognitive impairment can be an ongoing issue for patients with rheumatic disease, such as lupus. A proper diagnosis includes a battery of tests, says Noa Shwartz, M.D., a physician-researcher with Albert Einstein College of Medicine in New York.

September 21, 2020

Simultaneous use of more than one drug is gaining traction as a treatment strategy for severe lupus symptoms, particularly in people with chronic kidney disease.

September 21, 2020

Adherence to a Mediterranean diet is associated with improved musculoskeletal health and fewer falls, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting held earlier this month.

September 21, 2020

Low-dose oral glucocorticoid therapy increases only vertebral fracture risk in rheumatoid arthritis patients, a study shows.

September 18, 2020

Today, we talk with Dr. Sarah French, a rheumatologist with the University of California at San Francisco. Dr. French recently published a review in Current Osteoporosis Reports that addresses successes and failures in quality improvement initiatives in osteoporosis. Through the MIPS program, healthcare providers are required to select six quality measures. And while they may be performing well on osteoporosis screenings, their track record on osteoporosis management isn't fairing as well. Dr. French has identified this as an area for improvement. In this interview, she explains how.

September 18, 2020

In today’s one-on-one interview, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

September 16, 2020

Low levels of osteocalcin are associated with an increased risk of diabetes in patients treated with glucocorticoids, according to a study presented on Sept. 11 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which wrapped this week as a virtual meeting.

September 16, 2020

Improving vitamin D status might decrease the risk of developing severe respiratory distress and death in COVID-19 cases, shows an observational study presented September 11 at the American Society for Bone and Mineral Research (ASBMR) which was held virtually this week.

September 16, 2020

Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.

September 16, 2020

Teriparatide, a recombinant human parathyroid hormone analog [rhPTH(1-34)] approved for women and men with osteoporosis, has been shown to renew bone tissue in patients with femoral neck fractures of the hip, according to research presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held this week.